HilleVax (HLVX)

• Market cap: $92.6M
• 1 day: 1.64%
• 5 days: -6.53%
• 1 month: 3.91%
• 3 months: 3.33%
• 6 months: -85.50%
• Year to date: -87.77%
• 1 year: -87.30%
• 5 years: -90.26%
• 10 years: -90.26%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Employees: 90

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

44% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 18

7.75% less ownership

Funds ownership: 78.09% [Q2] → 70.34% (-7.75%) [Q3]

14% less funds holding

Funds holding: 91 [Q2] → 78 (-13) [Q3]

36% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 36

60% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 2 (-3) [Q3]

89% less capital invested

Capital invested by funds: $561M [Q2] → $61.7M (-$500M) [Q3]